International Navigator Hypoglycaemia Study

This study has been completed.
Sponsor:
Collaborators:
Karolinska Institutet
Schneider Children's Medical Center, Israel
Information provided by:
University Medical Centre Ljubljana
ClinicalTrials.gov Identifier:
NCT00843609
First received: February 12, 2009
Last updated: February 4, 2010
Last verified: June 2009
  Purpose

The purpose of this study is to determine if the incidence and duration of hypoglycaemia (low blood sugar) is reduced through the use of the FreeStyle Navigator Continuous Glucose Monitoring System in people with Type 1 diabetes mellitus at good glycemic control. The investigators hypothesize that the access to real-time continuous glucose concentration data along with alarms will enable people with type 1 diabetes at reasonable metabolic control to reduce the time spent in hypoglycaemia.


Condition Intervention
Diabetes Mellitus, Type 1
Hypoglycemia
Device: Navigator continuous glucose monitor (Freestyle Navigator®)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: International Navigator Hypoglycaemia Study: Evaluation of the Incidence and Duration of Hypoglycaemia Using the Freestyle Navigator® Continuous Glucose Monitoring System

Resource links provided by NLM:


Further study details as provided by University Medical Centre Ljubljana:

Primary Outcome Measures:
  • Reduction in time spent in hypoglycaemia, defined as continuous glucose <3.5mmol/l (63mg/dl) (with or without symptomatic hypoglycaemia). [ Time Frame: 6 months after randomisation ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • No concomitant rise in HbA1c [ Time Frame: 6 months after randomization ] [ Designated as safety issue: No ]
  • Glycaemic variability [ Time Frame: 6 months after randomization ] [ Designated as safety issue: No ]
  • Frequency and area under the curve (AUC) of hypoglycaemia [ Time Frame: 6 months after randomization ] [ Designated as safety issue: No ]
  • Quality of Life measures (Fear of Hypoglycaemia score and subject satisfaction questionnaire); [ Time Frame: 6 months after randomization ] [ Designated as safety issue: No ]

Enrollment: 122
Study Start Date: October 2008
Study Completion Date: January 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Continuous glucose monitoring
Continuously wearing the FreeStyle Navigator continuous glucose monitor, displaying real-time glucose values and sounding alarms
Device: Navigator continuous glucose monitor (Freestyle Navigator®)
Continuous use of the Free Style Navigator for monitoring of glycemia in patients with type 1 diabetes with HbA1c below 7.5 %
Other Name: Free Style Navigator
No Intervention: Control
Using SMBG with standard routine instructions

Detailed Description:

Background:

Real-time continuous glucose monitoring is expected to allow patients to reduce glycaemic fluctuations and to improve their ability to achieve tight glycaemic control without an increase in the incidence or fear of hypoglycaemia through the availability of high fidelity real-time glucose data and alarms throughout the day. As well as in adults, this may be particularly important in both children and adolescents with type 1 diabetes mellitus (T1DM).

Study Overview:

This is a multicentre, prospective, randomised, controlled, intervention study, being conducted at 3 study centres; Ljubljana in Slovenia, Tel Aviv in Israel and Stockholm in Sweden.

The aim is to enroll 100 subjects (50 adult and 50 paediatric), but enrolling up to 120 eligible subjects to allow for dropouts. The subject population will be randomly assigned 50:50 to either the control group or intervention group.

Subjects will be asked to participate for 7 months, consisting of a one-month 'run-in' period on SMBG followed by a 6-month test period. Enrolment will take place within a 16-week period. A blood sample will be taken for centralized baseline measurement of HbA1c. To be included in the study a subject must have an HbA1c level at inclusion below 7.5 % All subjects will undergo a one-month run-in period. Each subject will be given a FreeStyle blood glucose meter and strips to perform self monitoring of blood glucose (SMBG) according to their standard glycaemic management regime, as advised by their health care professional (HCP).

Subjects will then be required to return to the clinic at the end of the run-in period to have another blood sample taken for centralized measurement of HbA1c and to be randomly assigned to Group 1 (intervention) or Group 2 (control) for the next 6-month test period.

Group 1 will be required to use the FreeStyle Navigator CGM to manage their glycaemic control, wearing individual sensors for a series of five day durations, for the next six months.

Group 2 will continue in the study for the next 6 months using SMBG to manage their glycaemic control with the FreeStyle meter and strips provided. Every second week the subject will wear a 'masked' FreeStyle Navigator sensor for 5 days. Subjects will be encouraged to alternate the days that they wear the FreeStyle Navigator sensors, so that data is obtained from days in both the week and weekend.

Subjects will return to the clinic at 3 months and 6 months (after entering the study test-phase) for centralized HbA1c measurement. Subjects (and parents of paediatric subjects) within the intervention group will also be asked to complete a subject satisfaction questionnaire on their experience with the device.

  Eligibility

Ages Eligible for Study:   10 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject with Type 1 diabetes (> 1year since diagnosis)
  • CSII or MDI
  • HbA1c at inclusion < 7.5 %
  • No concomitant diseases that influence metabolic control
  • No current use of CGM

Exclusion Criteria:

  • Subject has known allergy to medical grade adhesives
  • Subject has a medical condition, which in the Investigator's opinion, may compromise patient safety
  • Subject is participating in another study of a glucose monitoring device or drug that could affect glucose measurements or glucose management
  • Subject is currently using another CGM device or has used real-time continuous glucose monitoring in the previous 4 weeks
  • Subject is receiving peritoneal dialysis solutions containing icodextrin
  • Female subject who is pregnant or planning to become pregnant within the planned study duration
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00843609

Locations
Israel
Schneider Children's Medical Center of Israel
Petah Tikva, Israel, 49202
Slovenia
UMC Ljubljana - University Children's Hospital
Ljubljana, Slovenia, 1000
Sweden
Karolinska Institutet
Stockholm, Sweden
Sponsors and Collaborators
University Medical Centre Ljubljana
Karolinska Institutet
Schneider Children's Medical Center, Israel
Investigators
Principal Investigator: Tadej Battelino, Prof. UMC Ljubljana
  More Information

No publications provided

Responsible Party: Tadej Battelino, MD,PhD, Professor of pediatrics, UMC Ljubljana
ClinicalTrials.gov Identifier: NCT00843609     History of Changes
Other Study ID Numbers: INHS1
Study First Received: February 12, 2009
Last Updated: February 4, 2010
Health Authority: Slovenia: Ministry of Health

Keywords provided by University Medical Centre Ljubljana:
diabetes mellitus, type 1
hypoglycemia
continuous glucose monitoring
HbA1c
glycemic variability

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Hypoglycemia
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on April 14, 2014